Advertisement

Drug Delivery and Translational Research

, Volume 9, Issue 1, pp 249–259 | Cite as

Macrophage ghost entrapped amphotericin B: a novel delivery strategy towards experimental visceral leishmaniasis

  • Prakash Kumar
  • Partha Pratim BoseEmail author
Original Article
  • 44 Downloads

Abstract

Leishmania donovani, an intracellular parasite, poses many challenges against attempted chemotherapy. After the resistance towards the first-line antileishmanial drug, amphotericin B has become the treatment of choice against visceral leishmaniasis, a fatal tropical disease. However, unfavorable toxicity profile, severe side effects, and prolonged parenteral administration limit its use. Lack of available specific delivery system also makes this drug unsafe for long-term use. In the current study, a “ghost cell” strategy based on macrophage membrane-derived nanovesicle has been introduced as a specific carriage for amphotericin B. Membrane proteins of macrophage ghost play a crucial role in the dissemination of infection in host by communicating between infected neutrophil-macrophage system and non-infected macrophages. These membrane proteins are the basis of specificity of the drug delivery to the infected tissues in this current macrophage ghost cell carrier. This cheap and biocompatible delivery vehicle has significantly improved the toxicity profile and lowered LD50 value of the drug compared to traditional way of its direct administration and widely accepted antileishmanial therapy, AmBisome.

Keywords

Amphotericin B Drug delivery Macrophage ghost Membrane-derived vesicle Visceral leishmaniasis 

Notes

Acknowledgements

PPB wishes to thank Amity Institute of Applied Sciences (AIAS), Amity University, Noida, India. PK acknowledges NIPER-Hajipur, Ministry of Chemicals and Fertilizers, Govt. of India.

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    WHO fact sheet; Leishmaniasis 2017; URL http://www.who.int/mediacentre/factsheets/fs375/en/ accessed on 17.01.18.
  2. 2.
    Sundar S, More DK, Singh MK, Singh VP, Sharma S, Makharia A, et al. Failure of pentavalent antimony in visceral leishmaniasisin India: report from the center of the Indian epidemic. Clin Infect Dis. 2000;31:1104–7.  https://doi.org/10.1086/318121.CrossRefGoogle Scholar
  3. 3.
    Chappuis F, Sundar S, Hailu A, Ghalib H, Rijal S, Peeling RW, et al. Visceral leishmaniasis: what are the needs for diagnosis, treatment and control? Nat Rev Microbiol. 2007;5:873–82.  https://doi.org/10.1038/nrmicro1748.CrossRefGoogle Scholar
  4. 4.
    Gradoni L, Soteriadou K, Louzir H, Dakkak A, Toz SO, Jaffe C, et al. Drug regimens for visceralleishmaniasis in Mediterranean countries. Tropical Med Int Health. 2008;13:1272–6.  https://doi.org/10.1111/j.1365-3156.2008.02144.x.CrossRefGoogle Scholar
  5. 5.
    Schwartzentruber DJ, Lawson DH, Richards JM, Conry RM, Miller DM, Treisman J, et al. gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. New Engl J Med. 2011;364:2119–27.  https://doi.org/10.1056/NEJMoa1012863.CrossRefGoogle Scholar
  6. 6.
    Xu Z, Ramishetti S, Tseng YC, Guo S, Wang Y, Huang L. Multifunctional nanoparticles co-delivering Trp2 peptide and CpG adjuvant induce potent cytotoxic T-lymphocyte response against melanoma and its lung metastasis. J Control Release. 2013;172:259–65.  https://doi.org/10.1016/j.jconrel.2013.08.021.CrossRefGoogle Scholar
  7. 7.
    McCarthy SA, Davies GL, Gun’ko YK. Preparation of multifunctional nanoparticles and their assemblies. Nat Protoc. 2012;7:1677–93.  https://doi.org/10.1038/nprot.2012.082.CrossRefGoogle Scholar
  8. 8.
    Hu CM, Zhang L, Aryal S, Cheung C, Fang RH, Zhang L. Erythrocyte membrane-camouflaged polymeric nanoparticles as a biomimetic delivery platform. Proc Natl Acad Sci U S A. 2011;108:10980–5.  https://doi.org/10.1073/pnas.1106634108.CrossRefGoogle Scholar
  9. 9.
    Furman NET, Lupu-Haber Y, Bronshtein T, Kaneti L, Letko N, Weinstein E, et al. Reconstructed stem cell nanoghosts: a natural tumor targeting platform. Nano Lett. 2013;13:3248–55.  https://doi.org/10.1021/nl401376w.CrossRefGoogle Scholar
  10. 10.
    Parodi A, Quattrocchi N, van de Ven AL, Chiappini C, Evangelopoulos M, Martinez JO, et al. Synthetic nanoparticles functionalized with biomimetic leukocyte membranes possess cell-like functions. Nat Nanotechnol. 2013;8:61–8.  https://doi.org/10.1038/nnano.2012.212.CrossRefGoogle Scholar
  11. 11.
    Belhadj S, Pratlong F, Toumi NH, Kallel K, Mahjoub H, Babba H, et al. Visceral leishmaniasis in Tunisia: result of the isoenzymatic characterization of 65 Leishmania infantum strains. Trans R Soc Trop Med Hyg. 2002;96:627–30.  https://doi.org/10.1016/S0035-9203(02)90332-9.CrossRefGoogle Scholar
  12. 12.
    Blackwell JM, Ezekowitz RA, Roberts MB, Channon JY, Sim RB, Gordon S. Macrophage complement and lectin-like receptors bind Leishmania in the absence of serum. J Exp Med. 1985;162:324–31 PMC2187694.CrossRefGoogle Scholar
  13. 13.
    Wilson ME, Pearson RD. Roles of CR3 and mannose receptors in the attachment and ingestion of Leishmaniadonovani by human mononuclear phagocytes. Infect Immun. 1988;56:363–9.Google Scholar
  14. 14.
    Gagnon E, Duclos S, Rondeau C, Chevet E, Cameron PH, Steele Mortimer O, et al. Endoplasmic reticulum-mediated phagocytosis is a mechanism of entry into macrophages. Cell. 2002;110:119–31.CrossRefGoogle Scholar
  15. 15.
    Hurrell BP, Regli IB, Tacchini-Cottier F. Different Leishmania species drive distinct neutrophil functions. Trends Parasitol. 2016;32:392–401.  https://doi.org/10.1016/j.pt.2016.02.003.CrossRefGoogle Scholar
  16. 16.
    Starr T, Bauler TJ, Malik-Kale P, Steele-Mortimer O. The phorbol 12-myristate-13-acetate differentiation protocol is critical to the interaction of THP-1 macrophages with Salmonella typhimurium. Plosone. 2018;13:e0193601.  https://doi.org/10.1371/journal.pone.0193601.CrossRefGoogle Scholar
  17. 17.
    Choi MR, Santon-Maxey KJ, Stanely JK, et al. A cellular Trojan horse for delivery of therapeutic nanoparticles into tumors. Nano Lett. 2007;7:3759–65.CrossRefGoogle Scholar
  18. 18.
    Lincopan N, Carmona-Ribeiro AM. Lipid-covered drug particles: combinedaction of dioctadecyldimethylammonium bromide and amphotericin B ormiconazole. J Antimicrob Chemother. 2006;58:66–75.CrossRefGoogle Scholar
  19. 19.
    Kumar P, Nagarajan A, Uchil PD. Analysis of cell viability by the MTT assay. Cold Spring Harb Protoc. 2018;2018:pdb.prot095505.  https://doi.org/10.1101/pdb.prot095505.CrossRefGoogle Scholar
  20. 20.
    Liu D, Uzonna JE. The early interaction of Leishmania with macrophages and dendritic cells and its influence on the host immune response. Front Cell Infect Microbiol. 2012;2(83).  https://doi.org/10.3389/fcimb.2012.00083.
  21. 21.
    Reis LC, Ramos-Sanchez EM, Goto H. The interactions and essential effects of intrinsic insulin-like growth factor-I on Leishmania (Leishmania) major growth within macrophages. Parasite Immunol. 2013;3:239–44.CrossRefGoogle Scholar

Copyright information

© Controlled Release Society 2018

Authors and Affiliations

  1. 1.Department of BiotechnologyNIPER-HajipurHajipurIndia
  2. 2.Amity Institute of Applied Sciences (AIAS)Amity UniversityNoidaIndia

Personalised recommendations